Kahn Swick & Foti Continues to Investigate CareDx, Inc.
Kahn Swick & Foti, LLC is actively investigating the officers and directors of CareDx, Inc. (NASDAQ: CDNA) as concerns about the company's business practices continue to rise. Led by former Louisiana Attorney General Charles C. Foti, Jr., the law firm is examining whether CareDx's leadership has effectively fulfilled their fiduciary responsibilities to shareholders.
Understanding CareDx's Services and Products
CareDx specializes in advancing healthcare for transplant patients. It offers innovative medical services and tests, including notable products such as AlloSure, AlloMap, and RemoTraC. These tools assist in monitoring transplant health and ensuring positive long-term outcomes for patients.
Legal Issues Facing CareDx
In recent months, CareDx has reported being under investigation by the U.S. Department of Justice and the SEC, which scrutinize the company's conduct related to its kidney testing and phlebotomy services. The investigations were disclosed by the company, revealing deeper problems tied to their operational practices.
Changes in Corporate Leadership
The company has endured significant turnover within its leadership. Notably, the resignation of its Chief Financial Officer and other key executives in 2022 raised red flags among investors. These leadership changes coincided with disappointing financial results, prompting further inquiry into the company's governance practices.
Financial Struggles
Financial disclosures from CareDx indicate troubling trends. The company reported a revenue decline in its diagnostic solutions sector and rising operational costs that outpaced revenue growth. This situation worsened to the extent that losses from operations almost doubled, impacting the outlook for the company's projects and investments.
Legal Action Against CareDx
Amidst these challenges, CareDx has also found itself embroiled in a securities class action lawsuit. The lawsuit stems from allegations that the company failed to disclose critical information, which is believed to have violated federal securities laws. The court has previously rejected the company's efforts to dismiss these claims, allowing the lawsuit to proceed.
Importance of Shareholder Rights
Kahn Swick & Foti's inquiry aims to safeguard the rights of shareholders and ensure they receive the transparency that is vital in corporate governance. The firm encourages any shareholders with relevant information to come forward and share their experiences, as they may significantly contribute to the ongoing investigation.
Contacting Kahn Swick & Foti for Assistance
If individuals have insights that could aid the investigation or want to learn about their legal options regarding CareDx, they can reach out without any obligation. The firm provides a toll-free number and contact options for long-term shareholders to voice their concerns.
About Kahn Swick & Foti, LLC
As one of the top boutique law firms specializing in securities litigation, Kahn Swick & Foti has gained a strong reputation for representing clients affected by corporate fraud. The firm's partners, including the well-respected Charles C. Foti, Jr., strive to recover losses endured by investors due to corporate mismanagement.
Frequently Asked Questions
What is the purpose of Kahn Swick & Foti's investigation?
The investigation aims to determine if CareDx's leadership has breached fiduciary duties and violated laws impacting shareholders.
What products does CareDx provide?
CareDx offers medical products for transplant patients, including AlloSure, AlloMap, and RemoTraC.
What legal challenges is CareDx facing?
CareDx is facing investigations by the DOJ and SEC, as well as a securities class action lawsuit for not disclosing important information.
How can shareholders participate in the investigation?
Shareholders can contact Kahn Swick & Foti for assistance and to share relevant information regarding their experiences with CareDx.
Who is Kahn Swick & Foti, LLC?
KSF is a prominent law firm that specializes in securities litigation, assisting investors in recovering losses from corporate fraud.
